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Abstract. 5-Fluorouracil (5-FU) is one of the most well 
established chemotherapeutic agents in the treatment of 
esophageal cancer. Ribonucleotide reductase M1 (RRM-1) is 
the rate-limiting enzyme in de novo DNA synthesis, and has 
been considered to play an important role in the 5-FU metabolic 
pathway. However, the means by which RRM-1 participates in 
the anticancer effects of 5-FU and cisplatin (CDDP) have not 
been well studied. Here, we show that RRM-1 significantly 
contributes to the induction of DNA damage by 5-FU in 
esophageal cancer cell lines. An assay of γ-H2AX focus forma-
tion, a marker of DNA damage, after 5-FU treatment revealed 
good correlation with the levels of RRM-1 protein expression. 
Moreover, the increased sensitivity and RAD51 focus forma-
tion induced by the combination treatment of 5-FU and CDDP 
were significantly repressed by RRM-1 depletion. These results 
suggest that RRM-1 is involved not only in the induction of 
DNA damage by 5-FU but also in the synergistic cytotoxic 
effect in the combination therapy of 5-FU and CDDP.
Introduction
Esophageal cancer is one of the most aggressive types of cancer 
and the eighth most common cause of cancer-related death in 
the world (1,2). In spite of recent advances in the development of 
anticancer and molecular target drugs, the combination regimen 
of 5-fluorouracil (5-FU) and cisplatin (CDDP) still plays an 
important role in the treatment of esophageal cancer, as the gold 
standard chemotherapy.
The nucleoside analogue 5-FU is converted to several 
active metabolites, including fluorouridine triphosphate 
(FUTP), fluorodeoxyuridine triphosphate (FdUTP) and fluoro-
deoxyuridine monophosphate (FdUMP), to exert its cytotoxic 
activity (Fig. 1). FUTP is largely incorporated into the RNA 
strand, preventing the processing and function of various types 
of RNA including mRNA, rRNA, tRNA and snRNA to exert 
anticancer effect of 5-FU (3). Recently, several lines of evidence 
suggest that these metabolites of 5-FU also interrupt DNA 
metabolism by misincorporation or enzyme inhibition (3). For 
example, FdUMP disturbs DNA replication by inhibiting the 
activity of thymidylate synthetase (TS), through the deple-
tion of dTMP. 5-FU may also generate DNA damage, such as 
DNA single-strand breaks and/or DNA double strand breaks 
(DSBs) via the collapse of stalled replication forks. Although 
the induction of DNA damage has been shown to play a role 
in the anticancer effect of 5-FU (4-6), the means by which the 
metabolites of 5-FU exert their anticancer effects through the 
disturbance of DNA or RNA metabolism remain obscure (7).
Several 5-FU related enzymes, such as dihydropyrimidine 
dehydrogenase (DPD), orotate phosphoribosyl transferase 
(OPRT), thymidine phosphorylase (TP) and ribonucleotide 
reductase (RNR), are considered as major determinants of 
the outcome of 5-FU treatment (8-10) (Fig. 1). Among these 
enzymes, ribonucleotide reductase, composed of large subunit 
RRM-1 and small subunit RRM-2, is the rate-limiting enzyme 
in de novo DNA synthesis (11). RNR converts fluorouridine 
diphosphate (FUDP) to fluorodeoxyuridine diphosphate 
(FdUDP), which preferentially affects DNA metabolism. 
Recently, RNR has also been shown to play an important role 
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in DNA repair (12). However, how RNR is involved in the regu-
lation of the anticancer effect of 5-FU remains to be clarified.
DNA damage, such as stalled replication forks and DSBs, 
induces the phosphorylation of histone H2AX on Ser-139 
(γ-H2AX), and the focus formation of γ-H2AX (γ-H2AX foci) 
(13). γ-H2AX is required to retain DNA repair proteins and 
checkpoint proteins at damaged sites, for the efficient processing 
of damaged DNA (14,15). Homologous recombination (HR) is 
a versatile DNA repair mechanism, because it can promote the 
elimination of a variety of lesions, including DSBs, single-strand 
gaps and stalled DNA replication forks (16,17). RAD51 is one 
of the key proteins for DNA repair by HR, since it mediates 
homologous pairing and strand exchange between DNA duplexes 
(18). RAD51 has also been shown to form nuclear foci at DSB 
sites (19). Since many anticancer drugs induce DNA damage, 
analyses of DNA repair proteins, such as γ-H2AX and RAD51, 
could be useful to predict the outcome of anticancer drugs 
(20-22). Recently, a dose-dependent increase in the number of 
γ-H2AX foci after 5-FU treatment was reported (23). CDDP 
also induces the γ-H2AX and RAD51 foci by the formation of 
interstrand and intrastrand DNA crosslinks, which lead to the 
formation of DSBs when they meet replication forks (24-26). 
Although the combination regimen of 5-FU and CDDP shows 
synergistic effects both in vitro and in vivo, the involvement of 
DNA damage in this effect remained to be clarified (27,28).
In this study, we investigated the mechanism of the anti-
cancer effect of 5-FU, by analyzing the kinetics of γ-H2AX and 
RAD51 foci formation in esophageal cancer cells. RRM-1 was 
required for the γ-H2AX focus formation after 5-FU treatment. 
Moreover, RRM-1 enhanced the formation of RAD51 foci, but 
not γ-H2AX foci, when cells were treated with 5-FU and CDDP 
in combination. These findings clearly suggest that RRM-1 is 
involved in the anticancer effect of 5-FU by modulating DNA 
repair in human esophageal cancer cells.
Materials and methods
Cell lines, culture medium and chemicals. Two esophageal 
carcinoma cell lines (TE1 and TE11) were obtained from the 
Cell Resource Center for the Biomedical Research Institute of 
Development, Aging and Cancer (Tohoku University, Sendai, 
Japan). TE1 is a well differentiated squamous cell carcinoma, 
and TE11 is a moderately differentiated squamous cell carci-
noma. These cell lines were routinely grown in RPMI-1640 
(Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal 
bovine serum, and incubated at 37˚C in a humidified atmosphere 
of 5% CO2 in air. 5-FU (Kyowa Hakko Co., Japan) and CDDP 
(Nihonkayaku Co., Japan) were dissolved in PBS at 1 mM.
Clonogenic assay for cell survival. The drug sensitivity of the 
cells was assessed by their colony forming ability. In brief, 
approximately 2.0x103 cells were seeded in a 60-mm tissue 
culture dish and incubated overnight. To assess the synergistic 
effect of 5-FU and CDDP, the concomitant treatment regimen 
involved the simultaneous treatment of cells with 5-FU (1-3 μM) 
for 24 h and CDDP (1-5 µM) for 1 h, alongside suitable controls 
of cells treated with appropriate doses of CDDP (0-10 µM) alone 
for 1 h, or 5-FU (0-10 µM) alone for 24 h. The cells were washed 
in PBS and cultured for 7-10 days in a 5% CO2 atmosphere at 
37˚C in air. The colonies were fixed with 100% methanol for 
10 min, and stained with Giemsa in phosphate buffer (pH 6.4). 
Colonies composed of 50 or more cells were scored as survi-
vors, and the surviving fraction for a given treatment dose was 
calculated as the relative plating efficiency of treated versus 
untreated (control) cultures. All experiments were performed 
three times and yielded similar results.
Dose-response curves were analyzed using the CalcuSyn 
Software (Biosoft), which is based on the median effect model 
of Chou and Talalay. A combination index (CI) of 1 indicated an 
additive drug interaction, whereas a CI of >1 was antagonistic 
and a score lower than 1 was synergistic.
Immunofluorescence analysis. The cells were seeded in 6-well 
plates containing coverslips, and were treated with 3 µM 5-FU 
for 24 h, 5 µM CDDP for 1 h, or the concomitant treatment, and 
were allowed to recover for the indicated periods. The coverslips 
were then fixed with 4% paraformadehyde at room temperature 
for 10 min. The cells were washed twice with 0.1% Triton X-100 
in PBS (PBS-T), permeablized with 0.5% Triton X-100 and 0.1% 
SDS in PBS for 10 min, and washed with 0.05% glycine and 
0.1% BSA in PBS (PBS+). The coverslips were incubated with 
the primary antibody at 37˚C for 90 min. The primary antibodies 
were used at the following ratios: anti-RAD51 (Calbiochem, 
La Jolla, CA, USA), 1:500; anti-γ-H2AX (Upstate Biotechnology, 
Lake Plasid, NY, USA) 1:40,000. The coverslips were incubated 
at 37˚C for 1 h with the secondary antibody, either sheep-anti-
mouse-Cy3 (BioSource, USA) at 1:400 or goat-anti-rabbit-FITC 
(Jackson ImmunoResearch Laboratories Inc., West Grove, PA, 
USA) at 1:500. DNA counter staining was accomplished with 
DAPI (4', 6-diamidino-2-phenylindole). After staining, the cover-
slips were sealed with VectaShield (Vector Laboratories Inc., 
Burlingame, CA, USA) and stored in the dark.
Images were obtained with a Zeiss Axiovert 200 M fluores-
cence microscope, using the AxioVision Rel 4.4 software (Carl 
Zeiss, Germany). Cells were scored as positive for damage-
Figure 1. Metabolism of 5-FU.
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induced foci if there were ≥15 spots per cell for γ-H2AX and ≥5 
for RAD51. About 200 cells were observed for each regimen, 
and the averaged data are from three independent experiments.
siRNA treatment. TE11 cells were transfected with either the 
non-targeting control (NT) siRNA (Dharmacon, Inc., USA) or 
the siRNA for human RRM-1 (GGAUCGCUGUCUCUAA 
CUUtt). The siRNA for human RRM-1 was kindly provided by 
Dr H. Niida (Department of Molecular Biology, Hamamatsu 
University School of Medicine, Shizuoka, Japan) (12). 
Transfection was performed 24 h before 5-FU and/or CDDP 
treatment using Lipofectamine 2000 (Invitrogen) according to 
the manufacturer's instructions, and the final concentrations of 
both the NT siRNA and RRM-1 siRNA were 1 nM in OptiMEM 
(Invitrogen) medium per well.
Immunoblot analysis. Cells were harvested and lysed in 
Laemmli's buffer. Total cell protein extracts were fractionated 
by SDS-PAGE using a multigel II (Cosmo Bio, Japan), and were 
electrophoretically transferred onto PVDF membranes. The 
membranes were blocked with 5% non-fat dried milk in TBS 
containing 0.1% Tween-20 (TBS-T) for 1 h. The membranes 
were then incubated with primary antibodies against β-actin 
(Sigma, St. Louis, MO, USA), RRM-1 or RRM-2 (Santa 
Cruz Biotechnology Inc., Santa Cruz, CA, USA) for 1 h. The 
membranes were then washed three times with TBS-T and incu-
bated with the appropriate secondary antibodies. After three 
washes with TBS-T, the immunoreactive proteins were visual-
ized by enhanced chemiluminescence (Amersham Biosciences, 
Uppsala, Sweden).
Flow cytometry for γ-H2AX analysis. The cells were harvested 
with 2% trypsin and washed three times in cold PBS. After 
permeation, the cells were incubated with the anti-γ-H2AX 
antibody (1: 40,000 dilution) for 1 h. The cells were washed and 
resuspended in the secondary antibody, sheep anti-mouse-Cy3 
(1:400 dilution), for 30 min. After fixation in 0.5% paraforma-
dehyde, the fluorescence emitted by Cy3 was measured by flow 
cytometry.
Statistical analysis. The differences in the cell viability and the 
percentage of focus formation of γ-H2AX and RAD51 between 
samples were evaluated with the Student's unpaired t-test. 
P<0.05 was regarded as statistically significant.
Results
Induction of DNA damage with 5-FU in esophageal cancer 
cell lines. To study the mechanisms of the anticancer activity 
of 5-FU, we investigated the survival of two esophageal cell 
lines, TE1 and TE11, after 5-FU treatment by a clonogenic 
assay. Representative dose-survival responses of 5-FU are 
depicted in Fig. 2A. The Dm values for 5-FU were estimated 
as 3.6 and 2.7 µM in TE11 and TE1, respectively. This indicates 
that there are no significant differences in the 5-FU sensitivi-
ties between these two cell lines.
Next, we examined the role of the induction of DNA damage 
in the anticancer effect of 5-FU (4,5). The formation of γ-H2AX 
foci at damaged sites is one of the highly sensitive markers of 
DNA damage induced by ionizing radiation and/or chemo-
therapeutic agents, such as CDDP (21). Therefore, we performed 
immunofluorescence staining of 5-FU-treated TE11 cells, using 
anti-γ-H2AX antibodies (Fig. 2B). The percentage of cells 
with γ-H2AX foci increased in a time-dependent manner. The 
peak was observed at 24 h after 5-FU exposure in TE11 cells 
(Fig. 2C). The flow cytometry analysis of γ-H2AX confirmed 
the increase in γ-H2AX positive TE11 cells after 5-FU treat-
ment (Fig. 2D). In contrast to TE11, TE1 cells failed to show 
an increase in γ-H2AX foci positive cells after 5-FU treatment 
(Fig. 2B-D). These findings suggest that 5-FU induces more 
DNA damage in TE11 cells, as compared to TE1 cells. Since 
the sensitivity of TE11 cells to 5-FU is similar to that of TE1 
(Fig. 2A), the mechanism by which 5FU exerts its anticancer 
effect could be different in these esophageal cell lines.
Metabolism of 5-FU in the two esophageal cancer cell lines. 
The difference in the induction of DNA damage by 5-FU in TE1 
and TE11 cells led us to examine the enzymes involved in the 
metabolism of the drug (3). The pharmacogenetic variability of 
5-FU-related enzymes, such as DPD, OPRT, TS and RNR, is 
associated with the anticancer activity of 5-FU (8-10). Among 
these enzymes, RNR is required to supply ribonucleotides for 
both DNA replication and repair (12). Thus, we examined the 
protein levels of the RNR subunits, RRM-1 and RRM-2, in the 
two cell lines, TE1 and TE11. The immunoblot analyses using 
the anti-RRM-1 antibody revealed that TE11 expressed a signifi-
cantly higher level of RRM-1, as compared to TE1 cells. The 
expression of RRM-2 was slightly higher in TE11 cells than TE1 
cells (Fig. 3A). The treatment of cells with 5-FU did not alter the 
expression of these enzymes. These results suggest that the high 
expression of RNR, especially RRM-1, in TE11 facilitates the 
induction of DNA damage, by converting 5-FU to 5-FdU.
To confirm the involvement of RRM-1 in the induction of 
DNA damage by 5-FU, we next examined the effect of RRM-1 
depletion in TE11 cells. RRM-1 depletion by the siRNA was 
confirmed by an immunoblot analysis of TE11 cells (Fig. 3B). 
To investigate the effect of RRM-1 depletion on DNA damage in 
TE11 cells, we first performed immunofluorescence staining of 
γ-H2AX after 5-FU treatment (Fig. 3C). The RRM-1 depletion 
by siRNA significantly repressed the γ-H2AX focus formation 
after 5-FU treatment (p<0.01) (Fig. 3D). This finding strongly 
supports the notion that RRM-1 is involved in the induction of 
DNA damage in TE11 cells after 5-FU treatment.
Next we investigated the survival of these cells after 5-FU 
treatment by a clonogenic assay, to determine whether RRM-1 
depletion is involved in 5-FU sensitivity. Representative dose-
survival responses of 5-FU are depicted in Fig. 3E. The Dm 
values for 5-FU were estimated as 3.34 µM in RRM-1 siRNA 
treated cells and 3.44 µM in control cells. Therefore, a signifi-
cant change in 5-FU sensitivity by the depletion of RRM-1 was 
not observed. The reduced anticancer activity of 5-FU, through 
the lower induction of DNA damage, might be compensated by 
the increased disturbance of RNA metabolism by the depletion 
of RRM-1.
Induction of DNA damage and damage response with the 
combination of 5-FU and CDDP in esophageal cancer cell 
lines. Having established that 5-FU induces DNA damage in 
TE11 cells, but not in TE1 cells, we elucidated the mechanism 
of the synergistic effect of the combination regimen of 5-FU and 
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CDDP. First we performed clonogenic assays to determine if the 
synergistic effect could be observed in the TE11 cell line. As a 
result, the co-incubation of TE11 cells with 5 µM CDDP and 
3 µM 5-FU showed the most significant synergistic inhibition of 
cell growth (Fig. 4A and B).
Since CDDP is a widely used platinum-containing anti-
cancer drug with an activity mechanism that involves the 
formation of DNA damage, we next examined the induction of 
DNA damage in TE11 cells after treatments with either CDDP 
alone or 3 µM 5-FU and 5 µM CDDP. Immunofluorescence 
staining of TE11 cells with the anti-γ-H2AX antibody 
revealed that CDDP alone and in the combination treatment 
induced γ-H2AX focus formation in a time-dependent manner 
(Fig. 5A and B). The percentage of γ-H2AX foci was slightly 
higher in the cells treated with the combination of 5-FU and 
CDDP than in those treated with CDDP or 5-FU alone. The 
peak was observed at 24 h after the combination regimen, and 
was similar to 5-FU alone (Fig. 5B). In contrast, the peak of 
γ-H2AX focus formation was observed at 12 h after CDDP 
treatment. Moreover, the increase in the percentage of γ-H2AX 
focus positive cells by the combinational treatment was addi-
tive. Therefore, the synergic effect may be due to a modulation 
of DNA repair, rather than an increase in the induction of DNA 
damage by the combinational treatment.
To further investigate the involvement of DNA damage 
induced by the combinational treatment in the synergic effect, 
we examined the kinetics of RAD51 focus formation, another 
DNA damage marker formed by a recombinational repair 
protein (Fig. 5A). Immunofluorescence analyses using an 
anti-RAD51 antibody revealed that the percentage of RAD51 
foci in TE11 cells was not significantly increased after a treat-
ment with 5-FU alone. While CDDP treatment slightly increased 
the percentage of RAD51 foci positive cells, the combinational 
treatment with 5-FU and CDDP drastically induced the 
RAD51 focus formation in TE11 cells (Fig. 5C). Interestingly, 
the increased focus formation of RAD51 persisted longer than 
that of γ-H2AX after the combinational treatment. Moreover, 
increase of the focus formation of RAD51 is more significant 
Figure 2. Toxicity in relation to the kinetics of γ-H2AX and RAD51 foci formation in esophageal cancer cell lines treated with 5-FU. (A) Cytotoxic effects on the 
TE11 and TE1 cell lines after a 24-h 5-FU exposure were determined using the clonogenic assay. Results are the means of at least three independent experiments, 
and error bars show the standard deviation of the mean. (B) Time-course of antibody-stained images of TE11 and TE1 cell lines treated with 3 µM 5-FU for 24 h. 
γ-H2AX and DNA (DAPI) are shown in red and blue, respectively. Scale bars, 20 µm. (C) Kinetics of γ-H2AX foci formation in TE11 and TE1 cell lines after 
a 24-h exposure to 3 µM 5-FU. All results are the means of three independent experiments, and error bars show the standard deviation of the mean. (D) Flow 
cytometric detection of γ-H2AX in TE11 and TE1 cell lines treated with 5-FU for 24 h.
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than that of γ-H2AX by the combinational treatment compared 
to either CDDP or 5-FU alone (Fig. 5B and C). Therefore, the 
modulation of DNA repair, rather than the increased induction 
of DNA damage, could contribute more to the synergic effect 
of the combinational treatment observed in TE11 cells.
RRM-1 is involved in the synergic effect of the combination 
treatment. We next examined if RRM-1 is involved in the 
synergic effect of the combinational treatment, since RRM-1 
plays a role in the 5-FU-induced DNA damage in TE11 cells 
(Fig. 3). We performed a clonogenic assay of RRM-1-depleted 
cells after the 5-FU/CDDP treatment. As expected, the depletion 
of RRM-1 with siRNA significantly increased the survival of 
TE11 cells after the combinational treatment (p<0.05) (Fig. 6A). 
Since RRM-1 depletion did not affect the 5-FU or CDDP sensi-
tivity of TE11 (Figs. 3E and 7C, p=0.90), this finding suggests 
the involvement of RRM-1 in the synergic effect of the combi-
nation regimen with 5-FU and CDDP in TE11 cells.
To study the role of RRM-1 in the synergic effect, we 
examined the effect of RRM-1 depletion on the induction of 
DNA damage after the combinational treatment of TE11 cells. 
Immunofluorescence staining with the anti-γ-H2AX antibody 
revealed that the depletion of RRM-1 by siRNA did not signifi-
cantly change the percentage of TE11 cells with γ-H2AX foci 
after the combinational treatment (p=0.86, Fig. 6B and D). The 
γ-H2AX focus formation was not significantly increased by 
Figure 3. Expression levels of RNR subunits and effect of RRM-1 depletion in the TE11 cell line. (A) Comparison of the RRM-1 and RRM-2 protein expression 
levels between TE11 and TE1 cells treated or untreated with 3 µM 5-FU for 24 h. (B) Expression levels of RRM-1 in TE11 cells transfected with RRM-1 siRNA 
(siRRM-1) or non-target siRNA (siNT). (C) Immunofluorescence staining of TE11 cells, using anti-γ-H2AX antibodies. Cells were transfected with RRM-1 
siRNA or NT siRNA before 5-FU treatment. γ-H2AX and DNA are shown in red and blue, respectively. Scale bars, 20 µm. (D) Percentage of γ-H2AX-positive 
cells, following a 3 µM 5-FU treatment for 24 h. All results are the means of three independent experiments, and error bars show the standard deviation of the 
mean. (E) Clonogenic assay of TE11 cells expressing either RRM-11 siRNA or NT siRNA, and treated with 5-FU for 24 h. Results are the means of at least three 
independent experiments, and error bars show the standard deviation of the mean.
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the combinational treatment, as compared to the treatments 
with 5-FU or CDDP alone (Fig. 5B). Moreover, the γ-H2AX 
focus formation after CDDP treatment was not affected by 
the RRM-1 depletion (Fig. 7A, p=0.21). Taken together, these 
findings strongly suggest that the facilitation of DNA damage 
induction by RRM-1 is not involved in the synergic effect of 
the combinational treatment.
If the synergic effect of the combinational treatment was not 
due to increased DNA damage by the combinational treatment, 
then the modulation of the repair system could be involved in this 
effect. To test this hypothesis, we next examined the effect of the 
depletion of RRM-1 on the RAD51 focus formation (Fig. 6C). 
Immunfluorescence analyses using an anti-RAD51 antibody 
revealed that, in contrast to γ-H2AX, RAD51 focus formation 
was significantly repressed by the depletion of RRM-1 in TE11 
cells, after the combinational treatment with 5-FU and CDDP 
(p<0.01) (Fig. 6E). In contrast, the RAD51 focus formation in 
TE11 cells treated with CDDP alone was not interrupted by the 
depletion of RRM-1 (Fig. 7B, p=0.15). Taken together, these 
findings suggest that RRM-1 is involved in the repair of the DNA 
Figure 4. Toxicity in TE11 cell lines treated with the combination of 5-FU and CDDP. (A) Several combinations of drug concentrations were tested, and their 
effects are shown. (B) Combination index is shown. Particularly, co-incubation of TE11 cells with 5 µM CDDP and 3 µM 5-FU showed the most synergistic 
inhibition of cell growth (Cl =0.788).
Figure 5. Toxicity in relation to the kinetics of γ-H2AX and RAD51 in TE11 cell lines treated with the combination of 5-FU and CDDP. (A) Immunostaining of 
TE11 cells using anti-γ-H2AX and RAD51 antibodies. Cells were treated with 3 µM 5-FU for 24 h and 5 µM CDDP for 1 h. γ-H2AX, RAD51 and DNA are shown 
in red, green and blue, respectively. Scale bars, 20 µm. (B and C) Kinetics of γ-H2AX and RAD51 focus formation in TE11 cells, after a 24-h exposure to 3 µM 
5-FU and a 1-h exposure to 5 µM CDDP. All results are the means of three independent experiments, and error bars show the standard deviation of the mean.
INTERNATIONAL JOURNAL OF ONCOLOGY  42:  1951-1960,  2013 1957
damage induced by the combinational treatment, but not by 
the CDDP treatment alone. Therefore, the modulation of DNA 
repair, rather than the increased induction of DNA damage, by 
the combinational treatment through RRM-1 activity could be 
responsible for the synergic effect of the combinational treat-
ment with CDDP and 5-FU in TE11 cells.
Discussion
In the present study, we showed that RRM-1, large subunit of 
RNR involved in the metabolism of 5-FU to 5-FdU, is required 
for the induction of DNA damage by 5-FU. Interestingly, 5-FU 
treatment significantly increased the CDDP-induced RAD51 
focus formation in an RRM-1-dependent manner. Taken 
together, these findings indicate that RRM-1 plays an impor-
tant role in the anticancer effect of combinational therapy of 
5-FU with CDDP through either the induction of DNA damage 
or modulation of DNA repair.
A significant synergistic inhibition of cell growth was 
observed after the combinational treatment with CDDP and 
5-FU. A recent report showed that the retention of DNA 
damage-induced γ-H2AX foci and RAD51 foci is apparently 
Figure 6. Effect of RRM-1 depletion on the induction of γ-H2AX and RAD51 focus formation in TE11 cells treated with the combination regimen. (A) The 
cytotoxicity of cells expressing either the NT siRNA (siNT) or RRM-1 siRNA (siRRM-1) was determined, using the clonogenic assay. Results are the means of 
at least three independent experiments, and error bars show the standard deviation of the mean. (B and C) Immunostaining of TE11 cells transfected with RRM-1 
siRNA and NT siRNA, using anti-γ-H2AX and RAD51 antibodies. Cells were treated with 3 µM 5-FU for 24 h and 5 µM CDDP for 1 h. γ-H2AX, RAD51 
and DNA are shown in red, green and blue, respectively. Scale bars, 20 µm. (D) Percentage of γ-H2AX foci-positive RRM-1 depleted cells, before and after the 
combinational treatment. All results are the means of three independent experiments, and error bars show the standard deviation of the mean. (E) Percentage of 
RAD51 foci-positive cells. All results are the means of three independent experiments, and error bars show the standard deviation of the mean.
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indicative of lethal DNA damage (29). The percentage of 
γ-H2AX-positive cells treated with the combination regimen 
was slightly higher than that treated with CDDP or 5-FU alone. 
Since both CDDP and 5-FU can induce DNA damage, this could 
be due to either the increased induction of DNA damage or the 
slowed DNA repair by the combinational treatment. The decline 
in the percentage of γ-H2AX-positive cells occurred earlier in 
the cells treated with CDDP, as compared to those subjected to 
the combinational treatment (Fig. 5B). Moreover, in contrast to 
the slight increase in γ-H2AX foci positive cells, the percentage 
of TE11 cells with RAD51 foci was significantly increased after 
the combinational treatment (Fig. 5C). Although we could not 
exclude the possible role of the increased induction of DNA 
damage, these findings strongly support the notion that slower 
DNA repair, due to the combinational treatment, plays a role in 
the synergic effect in TE11 cells treated with 5-FU and CDDP.
Figure 7. Effect of RRM-1 depletion on the induction of γ-H2AX and RAD51 focus formation in TE11 cells treated with CDDP alone. (A) Percentage of γ-H2AX 
foci-positive RRM-1 depleted cells (siRRM-1) and cells with treated with NTsiRNA (siNT), before and after CDDP treatment. All results are the means of three 
independent experiments, and error bars show the standard deviation of the mean. (B) Percentage of RAD51 foci-positive cells. All results are the means of three 
independent experiments, and error bars show the standard deviation of the mean. (C) The cytotoxicity of cells expressing either the NT siRNA or RRM-1 siRNA 
was determined, using the clonogenic assay. Results are the means of at least three independent experiments, and error bars show the standard deviation of the mean.
Figure 8. The suggested mechanism of the anti-cancer effect by the 5-FU/CDDP combinational treatment. RRM-1 could enhance the synergistic effect by 
increasing the complex forms of DNA damage.
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We found that RRM-1 plays important roles in the synergic 
effect of the combinational treatment with 5-FU and CDDP 
(Fig. 6A). However, the formation of γ-H2AX foci in cells 
treated with the combinational regimen was not affected by the 
depletion of RRM-1 (Fig. 6D). In contrast to the γ-H2AX focus 
formation, the depletion of RRM-1 significantly reduced the 
focus formation by RAD51, a recombinational repair protein, 
after the combinational treatment (Fig. 6E). Since RRM-1 is 
required for the production of FdUDP and FdUTP which could 
disturb DNA metabolism including repair, these findings also 
support the notion that the synergic effect of the combinational 
treatment is due to slower DNA repair requiring RAD51 (Fig. 8).
In spite of the requirement of RRM-1 for the induction of 
DNA damage, the expression levels of RRM-1 did not affect 
the survival of TE11 cells after 5-FU alone treatment (Fig. 3E). 
Metabolites of 5-FU can disturb either DNA or RNA metabo-
lisms (3). RRM-1 depletion could lead to increased conversion 
of 5-FU into 5-FUTP which contributes to the anticancer effect 
of 5-FU at several levels in RNA metabolism (30). The misin-
corporation of FUTP into RNA may inhibit the processing of 
pre-rRNA into mature rRNA (31,32). In addition, it may disrupt 
the post-transcriptional modifications of tRNAs (33,34) and the 
assembly and activity of snRNA/protein complexes, thus inhib-
iting the splicing of pre-mRNAs (35,36). Therefore, the decreased 
induction of DNA damage by the depletion of RRM-1 after 5-FU 
treatment could be compensated by the increased disturbance 
of RNA metabolism, through the increased level of 5-FUTP in 
TE11 cells. Still further investigation to clarify the disturbance of 
RNA metabolism by the RRM-1 depletion is required, RRM-1 
may play a key role in the regulation of the anticancer effect of 
5-FU alone by disturbing either DNA or RNA metabolism.
In this study, we found that RRM-1 is involved in the 
regulation of the anticancer effect of 5-FU, in single and combi-
national treatments with CDDP. Although further studies are 
required to clarify the role of RRM-1 in the synergic effect of 
the combinational therapy, the expression level of RRM-1 may 
be a useful predictive marker for the treatment of patients with 
the combination regimen of CDDP and 5-FU. Moreover, the 
modulation of RRM-1 expression could be a novel therapeutic 
strategy to enhance the effects of CDDP and 5-FU.
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